FDA grants breakthrough therapy designation for PADCEV plus KEYTRUDA
The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Astellas and Seattle Genetics’ jointly developed PADCEV (enfortumab vedotin-ejfv), in combination with KEYTRUDA (pembrolizumab), to